NCT03220646View on ClinicalTrials.gov

Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Brain Tumor
Interventions
DRUG

abemaciclib

abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.

DRUG

abemaciclib

200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery. Upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11725

Memorial Sloan Kettering Commack (All Protocol Activities), Commack

18103

Lehigh Valley Health Network, Allentown

06102

Hartford Healthcare Cancer Institute @ Hartford Hospital (Data collection only), Hartford

07920

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER